Ignite Creation Date:
2025-12-25 @ 1:26 AM
Ignite Modification Date:
2025-12-27 @ 4:59 AM
Study NCT ID:
NCT04320693
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2021-08-19
First Post:
2020-03-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access for IMMU-132
Sponsor:
Gilead Sciences
Organization:
Study Overview
Official Title:
Expanded Access for IMMU-132
Status:
APPROVED_FOR_MARKETING
Status Verified Date:
2020-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: